Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GCT-103
- Development stage
- Unknown
- Lead developer
- S-Quatre
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
GCT-103 is an investigational cell therapy being developed by Kidswell Bio (formerly Gene Techno Science) and its subsidiary S-Quatre Corporation, in collaboration with Nagoya University. The therapy utilizes stem cells derived from human exfoliated deciduous teeth (SHED), referred to as SQ-SHED. It is designed as a regenerative medicine approach for the treatment of pediatric cerebral palsy, aiming to address neurological damage. The cells can be administered as either allogeneic or autologous therapy via intravenous injection. It is currently in Phase 1/2 clinical development.
- Other names
- SQ-SHED cell therapyStem cells from human exfoliated deciduous teeth
Beyond the preview
Go deeper on GCT-103.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GCT-103.